Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 29, 2016 16:35 ET | Source: BeiGene, LTD.

BeiGene Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 with the PD-1 Antibody BGB-A317

WALTHAM, Mass., June 29, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly targeted and immuno-oncology drugs for the treatment...
June 06, 2016 08:00 ET | Source: BeiGene, LTD.

BeiGene to Participate in Goldman Sachs 37th Annual Global Healthcare Conference

WALTHAM, Mass., June 06, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (Nasdaq:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology...
June 05, 2016 09:00 ET | Source: BeiGene, LTD.

BeiGene Presents Initial Clinical Data on PD-1 Antibody BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting

WALTHAM, Mass., June 05, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and...
May 19, 2016 06:00 ET | Source: BeiGene, LTD.

BeiGene Announces Presentation on BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting

WALTHAM, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology...
May 11, 2016 16:15 ET | Source: BeiGene, LTD.

BeiGene Reports First Quarter 2016 Financial Results

WALTHAM, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology...
May 04, 2016 17:24 ET | Source: BeiGene, LTD.

BeiGene Appoints Dr. Ji Li as Executive Vice President, Global Head of Business Development

WALTHAM, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) (“BeiGene”), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology...
April 17, 2016 17:15 ET | Source: BeiGene, LTD.

BeiGene Presents Clinical Data for RAF Dimer Inhibitor BGB-283 at the 2016 American Association for Cancer Research Annual Meeting

WALTHAM, Mass., April 17, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) (“BeiGene”), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and...
April 11, 2016 17:00 ET | Source: BeiGene, LTD.

BeiGene Appoints Eric Hedrick, M.D. as Interim Chief Medical Officer

WALTHAM, Mass., April 11, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) (“BeiGene”), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and...
March 30, 2016 16:05 ET | Source: BeiGene, LTD.

BeiGene Reports Fourth Quarter and Full Year 2015 Financial Results

WALTHAM, Mass., March 30, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) (“BeiGene”), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and...
March 16, 2016 17:48 ET | Source: BeiGene, LTD.

BeiGene Announces Presentations on BGB-283 and Other Pipeline Agents at the 2016 American Association for Cancer Research Annual Meeting

WALTHAM, Mass., March 16, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) (“BeiGene”), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and...